Brentuximab vedotin/rituximab
- PDF / 170,324 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 92 Downloads / 150 Views
1 S
No therapeutic response: 4 case reports In a case series of 7 patients, four patients including 2 girls and 1 man [not all sexes stated] aged 5-32 years were described, who exhibited no therapeutic response during treatment with rituximab or brentuximab vedotin for lymphoproliferative disorder [dosages and routes not stated]. Patient 3: The girl was admitted to a hospital at the age of 5 years and 2 months and diagnosed with lymphoproliferative disorder. Initially, she received treatment rituximab and various other medications with a complete response. Thereafter, she was diagnosed with interleukin-2-inducible T-cell kinase (ITK) deficiency. After six months, she again developed lymphoproliferative disorder and received three additional doses of rituximab without benefits. Hence, she received second line treatment with brentuximab vedotin with a parial response. Patient 4: The girl had recurrent respiratory infections since early childhood. At the age of 6 years, she was diagnosed with lymphoproliferative disorder and showed CD27 deficiency. She received treatment with rituximab injection 375 mg/m2. Total such five injections were given without response. Hence, second line treatment with brentuximab vedotin was given and showed stable disease. Patient 6: The man was diagnosed with ADA deficiency from early childhood and tied various therapies. At the age of 24 years and 8 months, he was diagnosed with lymphoproliferative disorder. He received treatment with chemoradiotherapy with complete response. At the age of 27 years, he again developed lymphoproliferative disorder and received first line treatment with brentuximab vedotin without response. Hence, he was treated with various chemotherapy medications and showed a complete response. He later underwent allogenic haemopoietic stem cell transplantation, but eventually died due to transplant-related complications. Patient 7: The patient was diagnosed with lymphoproliferative disorder at the age of 11 years and received treatment with various chemotherapy medications with complete response. At the age of 32 years, the patient again developed lymphoproliferative disorder and received four doses of rituximab without response. Hence, second line treatment with brentuximab vedotin was provided, which led to complete response. Pincez T, et al. Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies. Haematologica 105: E461-E464, 803516127 No. 9, Sep 2020. Available from: URL: http://doi.org/10.3324/haematol.2019.230276
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
